CARE™ Reports

CARE™ Perspectives Report: DDW/ECCO 2021

Gastroenterology

05 Aug 2021

Introduction

The 2021 virtual DDW and ECCO meetings both showcased exciting research that will advance the management of inflammatory bowel disease (IBD) in Canada. This CARE report highlights key news and its potential impact for Canadian health care providers
and patients.

Please visit https://ddw.org/education/abstracts/ for more information and links to the various options for accessing the full DDW abstract content.

The links to access full ECCO abstract content have been incorporated within this report.

Abstracts Covered in Report
Existing Therapies

DDW 2021 775d. Ustekinumab Versus Adalimumab for Induction And Maintenance Therapy In Moderate-To-Severe Crohn’s Disease: The SEAVUE Study.
Sands et al.

CARE™ Gastroenterology Faculty Perspective
The SEAVUE trial was the first head-to-head comparison of existing therapies reported in Crohn’s disease. While SEAVUE failed to demonstrate superiority of ustekinumab over adalimumab, it did highlight that both of these agents are associated with high rates of clinical and endoscopic response and rapid onset of action, with favourable safety.

DDW 2021 742. Discontinuation Of Infliximab Therapy In Patients With Crohn’s Disease In Sustained, Complete ClinicalBiochemical-Endoscopic Remission: A Double-Blinded, Placebo-Controlled, Randomized Clinical Trial.
Buhl et al.

“These data provide a sobering reminder that remission of IBD is often sustained because of and not despite continued therapy.”

New Agents

DDW 2021 775a. Risankizumab Induction Therapy In Patients With Moderate-To-Severe Crohn’s Disease With Intolerance Or Inadequate Response To Conventional And/Or Biologic Therapy: Results From The Phase 3 ADVANCE Study.
D’Haens et al.

CARE™ Gastroenterology Faculty Perspective
Rizankizumab showed strong efficacy over placebo for induction of clinical remission and endoscopic improvement with reassuring safety, in both bio-naïve and bio-failure subgroups.

DDW 2021 648. Efficacy And Safety Of Filgotinib As Induction Therapy For Patients With Moderately To Severely Active Ulcerative Colitis: Results From The Phase 2B/3 SELECTION Study.
Feagan et al.

Conclusion: Both doses of FIL were well tolerated.

– 

ECCO 2021 OP24. Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study.
Danese et al.

CARE™ Gastroenterology Faculty Perspective
U-ACHIEVE confirmed the previously reported U-ACCOMPLISH in finding strong efficacy for upadacitinib.

Novel Concepts

ECCO 2021 OP31. RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s Disease.
Bressler et al.

CARE Gastroenterology Faculty Perspective
These preliminary data in Crohn’s disease are encouraging and suggest that this novel
therapeutic approach warrants further formal study.

DDW 2021 Su472. A Translational Phase I Study Of Tauroursodeoxycholic Acid (TUDCA) To Reduce Symptoms And Er Stress In Active Ulcerative Colitis.
Huang et al.

CARE Gastroenterology Faculty Perspective
These data reflect our greater understanding of the pathogenesis of IBD and reinforce that there is more to its treatment than immune suppression.

Additional Content
Abstract Spotlight: DDW 2021 775d.